Accéder au contenu
Merck
Toutes les photos(1)

Documents

71400-M

Sigma-Aldrich

Rosetta 2(DE3) Singles Competent Cells - Novagen

Escherichia coli, rod shaped

Synonyme(s) :

BL21 derivatives

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
41106202
Nomenclature NACRES :
NA.81

product name

Rosetta 2(DE3) Singles Competent Cells - Novagen, Novagen′s Rosetta 2 host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli.

Source biologique

Escherichia coli

Niveau de qualité

Fabricant/nom de marque

Novagen®

Conditions de stockage

OK to freeze

Mode de croissance

adherent or suspension

Morphologie

rod shaped

Technique(s)

microbiological culture: suitable

Transformation cellulaire

transformation efficiency: >2×106 cfu/μg

Conditions d'expédition

dry ice

Température de stockage

−70°C

Description générale

Genotype: F-ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 (CamR)





This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
A common method for transformation of DNA plasmids into E. coli is the use of chemically competent cells. Although competent cells can be prepared in the laboratory, greater efficiency, reproducibility, and convenience are achieved using Novagen prepared competent cells. Novagen® Singles Competent Cells are designed for ultimate convenience and reliability in plasmid transformation. Chemically competent cells are prepared using an optimized method. Cells are provided in 50µl volumes, eliminating the need to aliquot, freeze/thaw, or waste partially used vials, saving time and money and ensuring reliable cell performance. To use, simply thaw, add DNA, incubate 5 minutes on ice, heat shock for 30 seconds, place on ice for 2 minutes, and add SOC medium.T7 expression strains are lysogens of bacteriophageDE3, as indicated by the (DE3). These hosts carry achromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in appropriate T7 expression vectors, using IPTG as an inducer.
Rosetta 2 host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli. These strains supply tRNAs for 7 rare codones (AGA, AGG, AUA, CUA, GGA, CCC, and CGG) on a compatible chloramphenicol-resistant plasmid. The tRNA genes are driven by their native promoters.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.
Novagen′s Rosetta 2 host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins that contain codons rarely used in E. coli.

Composants

•11 rxn or 22 rxnRosetta 2(DE3) Competent Cells

•2 × 2 ml or 4 × 2 mlSOC Medium

•10 µlTest Plasmid

Avertissement

Toxicity: Multiple Toxicity Values, refer to MSDS (O)

Informations légales

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 2


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Fatma Betul Ertem et al.
STAR protocols, 3(1), 101158-101158 (2022-02-24)
The SARS-CoV-2 main protease of (Mpro) is an important target for SARS-CoV-2 related drug repurposing and development studies. Here, we describe the steps for structural characterization of SARS-CoV-2 Mpro, starting from plasmid preparation and protein purification. We detail the steps
Serdar Durdagi et al.
Structure (London, England : 1993), 29(12), 1382-1396 (2021-08-18)
The COVID-19 pandemic has resulted in 198 million reported infections and more than 4 million deaths as of July 2021 (covid19.who.int). Research to identify effective therapies for COVID-19 includes: (1) designing a vaccine as future protection; (2) de novo drug

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique